Literature DB >> 10602319

Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function.

T K Jeffery1, J C Wanstall.   

Abstract

1. Hypoxic pulmonary hypertension in rats (10% O2, 4 weeks) is characterized by changes in pulmonary vascular structure and function. The effects of the angiotensin converting enzyme inhibitor perindopril (oral gavage, once daily for the 4 weeks of hypoxia) on these changes were examined. 2. Perindopril (30 mg kg-1 d-1) caused an 18% reduction in pulmonary artery pressure in hypoxic rats. 3. Structural changes (remodelling) in hypoxic rats included increases in (i) critical closing pressure in isolated perfused lungs (remodelling of arteries <50 microm o.d.) and (ii) medial wall thickness of intralobar pulmonary arteries, assessed histologically (vessels 30 - 100 and 101 - 500 microm o.d.). Perindopril 10 and 30 mg kg-1 d-1 attenuated remodelling in vessels < or = 100 microm (lungs and histology), 30 mg kg-1 d-1 was effective in vessels 101 - 500 microm but neither dose prevented hypertrophy of main pulmonary artery. 3 mg kg-1 d-1 was without effect. 4. Perindopril (30 mg kg-1 d-1) prevented the exaggerated hypoxic pulmonary vasoconstrictor response seen in perfused lungs from hypoxic rats but did not prevent any of the functional changes (i.e. the increased contractions to 5-HT, U46619 (thromboxane-mimetic) and K+ and diminished contractions to angiotensins I and II) seen in isolated intralobar or main pulmonary arteries. Acetylcholine responses were unaltered in hypoxic rats. 5. We conclude that, in hypoxic rats, altered pulmonary vascular function is largely independent of remodelling. Hence any drug that affects only remodelling is unlikely to restore pulmonary vascular function to normal and, like perindopril, may have only a modest effect on pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602319      PMCID: PMC1571774          DOI: 10.1038/sj.bjp.0702923

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures.

Authors:  Z A Niazova; T A Batyraliev; K S Aikimbaev; G Z Kudaiberdieva; F Akgul; Y K Soodanbekova; A Birand
Journal:  J Hum Hypertens       Date:  1996-09       Impact factor: 3.012

2.  Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Authors:  Z Nong; J M Stassen; L Moons; D Collen; S Janssens
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

3.  Relationship between cardiovascular hypertrophy and cardiac baroreflex function in spontaneously hypertensive and stroke-prone rats.

Authors:  N Minami; G A Head
Journal:  J Hypertens       Date:  1993-05       Impact factor: 4.844

4.  Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension.

Authors:  J C Wanstall; I E Hughes; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 5.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

6.  Responses to pressure and vasoactive agents by isolated pulmonary arteries from monocrotaline-treated rats.

Authors:  J A Madden; P A Keller; R M Effros; C Seavitte; J S Choy; A D Hacker
Journal:  J Appl Physiol (1985)       Date:  1994-04

7.  Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies.

Authors:  D Vranes; M E Cooper; R J Dilley
Journal:  J Vasc Res       Date:  1995 May-Jun       Impact factor: 1.934

8.  Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.

Authors:  N W Morrell; E N Atochina; K G Morris; S M Danilov; K R Stenmark
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

9.  Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.

Authors:  N W Morrell; K G Morris; K R Stenmark
Journal:  Am J Physiol       Date:  1995-10

10.  Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries.

Authors:  G J Dusting; R Hyland; H Hickey; M Makdissi
Journal:  Am J Cardiol       Date:  1995-11-24       Impact factor: 2.778

View more
  7 in total

1.  Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review.

Authors:  Djuro Kosanovic; Xia Tian; Oleg Pak; Ying-Ju Lai; Yi-Ling Hsieh; Michael Seimetz; Norbert Weissmann; Ralph Theo Schermuly; Bhola Kumar Dahal
Journal:  Pulm Circ       Date:  2013-11-11       Impact factor: 3.017

Review 2.  Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.

Authors:  Chastity N Bradford; Debra R Ely; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

3.  Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung.

Authors:  Yoshiyuki Tanabe; Yuki Morikawa; Takao Kato; Satoshi Kanai; Taichi Watakabe; Ami Nishijima; Hijiri Iwata; Kaori Isobe; Mayumi Ishizaki; Koichi Nakayama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-07       Impact factor: 3.000

4.  S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats.

Authors:  Debbie Y Y Tsui; Agatha Gambino; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  Mitigation of radiation induced pulmonary vascular injury by delayed treatment with captopril.

Authors:  Robert C Molthen; Qingping Wu; Brian L Fish; John E Moulder; Elizabeth R Jacobs; Meetha M Medhora
Journal:  Respirology       Date:  2012-11       Impact factor: 6.424

6.  Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: effects of exposing rats to hypoxia.

Authors:  Janet C Wanstall; Steven A Fiore; Agatha Gambino; Russell Chess-Williams
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-06       Impact factor: 3.000

7.  Effects of Normoxic Recovery on Intima-Media Thickness of Aorta and Pulmonary Artery Following Intermittent Hypoxia in Mice.

Authors:  Akira Umeda; Kazuya Miyagawa; Atsumi Mochida; Hiroshi Takeda; Kotaro Takeda; Yasumasa Okada; David Gozal
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.